AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06726564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT027 cells suspension
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Study NCT06725407 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cesarean section
Description: In the study, the participants' postoperative hypothermia development status was monitored.
Study NCT06726057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imlementation strategies in conjunction with multicomponent hypertension intervention
Description: In this study, the researchers will develop and test strategies for the implementation and scale-up of a proven multicomponent hypertension intervention (MCHI) programme in Pakistan. Implementation strategies will be devised through an engagement process and will involve the use of implementation frameworks including the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to the implementation of MCHI\&amp;amp; Expert Recommendations for Implementation Change (ERIC) to identify a set of implementation strategies addressing each barrier. Input for the development of strategies will be sought from the community, public health sector managers, general practitioners and community health workers. The implementation strategies will be used to randomise study clusters while MCHI will be implemented in both intervention and control arms.
Study NCT06726057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent hypertension intervention
Description: The multicomponent hypertension intervention has four components as follows:~1. Training of community health workers (CHWs) in conducting health education sessions regarding hypertension, its risk factors, prevention, and health-seeking~2. Blood pressure (BP) monitoring and referral of hypertensive individuals by CHWs to general practitioners in primary care facilities~3. Training of general practitioners in primary care settings in BP monitoring and management of hypertension~4. Establishing hypertension triage counters and care coordinators in primary care facilities for the care of referred patients.
Study NCT05745441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Late Dinner tracer
Description: Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
Study NCT06725771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline
Description: Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously
Study NCT06725771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline Hydrochloride Tablets
Description: Sertraline are given to patients simultaneously
Study NCT06727097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography
Description: Successful completion of all four indices of the mCTSIB, without severe imbalance (i.e., near fall with safety harness and urgent knee to grab emergency handlebars) constitutes PSR +, non-completing on any of the index is noted as PSR -. Exploratorily, the average sway velocity index will be captured for each condition, to characterize sensory reweighting patterns.
Study NCT06727097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Walking Speed
Description: The 10-meter walk test (10MWT) is the gold standard measure of post-stroke walking function that reflects overall mobility and health status. Method: Two 10MWT trials (using a stopwatch) are averaged and documented in meters/second. The functional ambulatory category (FAC) will be collected as supplement. Exploratorily: Participants will also perform the 10mWT (fast paced-FP) with two attempts. Both SS and FP will be performed over the Zeno Walkway Gait Analysis Mat, to capture supplementary spatiotemporal data.
Study NCT06727097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Instrumented 7M Timed UP and GO
Description: This sub-aim will use iTUG to determine the effects of BLT on dynamic balance. In contrast to the traditional TUG, inclusion of wearable triaxial accelerometers and gyroscopes-placement test increases the sensitivity (87%) and specificity (87%) for identifying individuals prone to falls. Two trials are averaged and documented in seconds. Secondary analysis will be performed on data obtained from the sensors to determine (stride length, stride velocity, cadence, peak arm swing velocity, and turning velocity, during the task), to correlate with the TUG time/speed. Time points: Same as Posturography and 10 MWT.
Study NCT06727097 — intervention group
Intervention type: OTHER
Intervention: Fall Event Records
Description: A robust fall incident journal elucidating the date, time, nature, and management of the fall event will be provided to all study participants for documentation. The study research coordinator will contact the patient/caregiver/facility to collect the data q2 weeks. A tally of the total number of fall events between visits will be recorded.
Study NCT06727097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (3T)
Description: Structural neuroimaging biomarkers:. The fractional anisotropy map from the primary fiber population in each voxel will be resampled to MNI space (using the warp derived from structural preprocessing) and projected onto a template white matter skeleton using local maxima to further optimize registration accuracy. Small vessel disease parameters, including white matter hyperintensities using the Fazekas scale and number/site of microhemorrhages, will be recorded for exploratory analyses.
Study NCT06196567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions
Study NCT06196567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
Study NCT06196567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
Study NCT04766177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: bumetanide 0.5 mg twice daily
Study NCT04766177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets twice daily
Study NCT05435261 — intervention group
Intervention type: PROCEDURE
Intervention: BKA
Description: Below Knee Amputation:~* Under spinal anesthesia~* BKA~* closure in layers (terminal closure) with suction drain.
Study NCT05435261 — intervention group
Intervention type: PROCEDURE
Intervention: Debridement with Ex_Fix (salvage)
Description: Debridement and External Fixation (salvage):~* Under spinal anesthesia~* wound debridement and wash.~* external fixation.
Study NCT05032781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial cold saline, minocycline, and magnesium
Description: See study design
Study NCT06401135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: IMT will be conducted using a pressure threshold-loading device (POWERbreathe® Classic Low Resistance). The groups will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department. physiotherapist
Study NCT04221100 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.
Study NCT04221100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.
Study NCT06005311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfluidic chip
Description: The Sperm Separation Device - ZyMōt Multi 850µL (ZyMōt Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 μL of the semen sample will be inserted into the inlet port of the device and 750 μL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 μL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.
Study NCT06005311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Density-gradient centrifugation
Description: After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
Study NCT05185791 — intervention group
Intervention type: OTHER
Intervention: Pre-ERAS® phase (current clinical practice)
Description: Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
Study NCT05185791 — intervention group
Intervention type: OTHER
Intervention: Post-ERAS® implementation phase
Description: Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
Study NCT05676541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements
Description: The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
Study NCT04990128 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aspire Needle + Emcyte PureBMC
Description: The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.
Study NCT04990128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
Study NCT05759897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535
Study NCT05759897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06527326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Combined Bifidobacterium
Description: the Bifidobacterium genus supplement
Study NCT06527326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04675489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Procedure: Vivity Toric IOL
Description: The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
Study NCT05070507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enzyme containing lozenge
Description: Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
Study NCT05070507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge
Description: Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
Study NCT05346198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-BCMA
Description: The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
Study NCT05280392 — intervention group
Intervention type: OTHER
Intervention: Self-administered questionnaires
Description: 4 self-questionnaires given to EHVA T02 participants: at inclusion (Q1, week 0), at the beginning of the ATI period (Q2, week 18), at the end of the ATI period (Q3, date depending on the participant) and at the end of the follow-up period of the clinical trial (Q4, week 54 at the latest)
Study NCT05280392 — intervention group
Intervention type: OTHER
Intervention: Semi-directive individual interviews
Description: With EHVA T02 participants (n=10 to 15): at the end of the follow-up period of the clinical trial.
Study NCT05280392 — intervention group
Intervention type: OTHER
Intervention: Semi-directive individual interviews
Description: With patients who refused to participate to EHVA T02 or patients not included because of negative screening results (n=10 to 15): within 21 days after the refusal or the results of the screening
Study NCT05308511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC-I and COLON2
Description: First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
Study NCT05308511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLON2 and PC-I
Description: First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
Study NCT05586178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder that facilitates action
Description: Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
Study NCT05586178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consistency framing
Description: The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
Study NCT05586178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision about the uniqueness of the bivalent booster
Description: The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
Study NCT05586178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision about bivalent booster eligibility
Description: The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
Study NCT05586178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision about the severity of COVID-19 symptoms
Description: The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
Study NCT06039566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV N-acetylcysteine
Description: N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
Study NCT06039566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
Study NCT05983939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-791
Description: Single and multiple ascending oral doses of PIPE-791 tablets.
Study NCT05983939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single and multiple ascending oral doses of matching placebo tablets.
Study NCT06220916 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
Study NCT06537505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Q3W,IV
Study NCT06537505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: QoD
Study NCT06537505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: microwave ablation
Study NCT05251779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volatile Oil of Cang-Ai
Description: The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
Study NCT05251779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bergamot essential oils
Description: The control group will be given Bergamot essential oils for inhalation.
Study NCT06540872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46
Description: Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
Study NCT05538039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distract with play dough
Description: Distract with play dough
Study NCT05538039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distract with play kaleidoscope
Description: Distract with play kaleidoscope
Study NCT05538039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Routine nursing care
Study NCT05497219 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videofluoroscopic Swallowing Study (VF)
Description: A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
Study NCT06425718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Pain Management Technique
Description: Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
Study NCT05753592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1; LOU064 (Remibrutinib)
Description: 25 mg remibrutinib (5.5 days)
Study NCT05753592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2; LOU064 (Remibrutinib)
Description: 25 mg remibrutinib (5.5 days)
Study NCT05295875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)
Study NCT05185674 — intervention group
Intervention type: OTHER
Intervention: Exposure: Coronavirus disease 2019 (COVID-19)
Description: Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
Study NCT05295875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study NCT05664711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug.
Study NCT05946629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with SELUTION SLR DCB
Description: After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.